State Street Corp Has $6.97 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

State Street Corp boosted its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 4.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,469,068 shares of the company’s stock after buying an additional 150,647 shares during the quarter. State Street Corp owned approximately 1.69% of Taysha Gene Therapies worth $6,973,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Creative Planning bought a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $28,000. Principal Financial Group Inc. acquired a new stake in Taysha Gene Therapies in the second quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. lifted its stake in Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after acquiring an additional 17,446 shares during the last quarter. Intech Investment Management LLC bought a new stake in Taysha Gene Therapies in the third quarter worth approximately $85,000. Finally, Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter worth $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $1.75 on Friday. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a market cap of $358.65 million, a P/E ratio of 2.78 and a beta of 0.78. The business’s 50 day moving average is $2.12 and its two-hundred day moving average is $2.25.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.